RE: “If it wasn’t activating, would tolerability be an issue?”24 Nov 2022 13:45
Well, clearly its not to discuss the SP .
What seems to be missed here is that with the best will in the world no one here knows whats is going on and to what level.
We can all read the RNS's and interpret them how we want. Look at the differing views on biopsi data. Look at the discussions on safety/tolerability.
Every view has somebody saying the opposite based on what they believe is most likely and what the latest RNS for eg, "REALLY" means
We had discussions on what Pfizer do on trial data, then were they blinded trials, or were there patients in the hundreds rather than the handful or so in the DE's? How did that take us any further forward as to when the trial data will be released?
If you are going to use data and results and hard facts to determine when to buy a stock like this then you would wait until that info was in the public domain.
But we don't, we take a risk that we think it will most likely be ok and buy in front of this data.
Why you all get on your high horses about "understanding" what is taking place is amusing to say the least.
I don't mind in the slightest these conversations taking place but lets not kid ourselves that they help determine the results, of which all all of us have done for the last 18 months, is speculate about.